GeneDx Holdings (WGS) Total Current Liabilities (2020 - 2026)

GeneDx Holdings (WGS) has reported Total Current Liabilities for 7 consecutive years, with $74.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Current Liabilities rose 4.51% year-over-year to $74.6 million in Q2 2026; TTM through Jun 2026 was $74.6 million, a 4.51% increase from a year earlier, with the FY2025 full-year figure at $108.9 million, up 98.68% from the prior year.
• Total Current Liabilities was $74.6 million for Q2 2026 at GeneDx Holdings, down from $87.6 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $204.6 million in Q2 2022 and troughed at $50.7 million in Q1 2024.
• A 5-year average of $94.1 million and a median of $80.9 million in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities soared 181.77% in 2022 and sank 59.24% in 2023, its largest moves.
• Over 5 years, Total Current Liabilities stood at $144.3 million in 2022, then slumped by 59.24% to $58.8 million in 2023, then declined by 6.8% to $54.8 million in 2024, then jumped by 98.68% to $108.9 million in 2025, then slumped by 31.48% to $74.6 million in 2026.
• The last three Total Current Liabilities figures came in at $74.6 million (Q2 2026), $87.6 million (Q1 2026), and $108.9 million (Q4 2025), per Business Quant data.